ProCE Banner Activity

A Global Perspective on Emerging BTK Inhibitor Therapy Data for CLL and MCL in 2022

Slideset Download
Conference Coverage
Download this living slideset featuring new data from conference presentations on the use of BTK inhibitors to treat CLL and MCL. This slideset will be updated throughout 2022 and include key findings from the ASCO, EHA, Pan Pacific, ESMO, and SOHO annual meetings, so check back often.

Released: October 10, 2022

Expiration: October 09, 2023

No longer available for credit.

Share

Faculty

Othman Al-Sawaf

Othman Al-Sawaf, MD

Medical Doctor
Dep I of Internal Medicine
University Hospital of Cologne
Cologne, Germany

Anthony Mato

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Lydia Scarfò

Lydia Scarfò, MD

Assistant Professor
Internal Medicine
Università Vita-Salute San Raffaele
Consultant Hematologist
Strategic Research Program on CLL
Milan, Italy

Julie M. Vose

Julie M. Vose, MD

Neumann M. and Mildred E. Harris Professor
Chief
, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Othman Al-Sawaf, MD

Medical Doctor
Dep I of Internal Medicine
University Hospital of Cologne
Cologne, Germany

Othman Al-Sawaf, MD: honoraria: AbbVie, Adaptive Biotechnologies, Ascentage, AstraZeneca, BeiGene, Gilead, Janssen-Cilag, Roche; consulting/advisory: AbbVie, Janssen-Cilag, Gilead, Roche; research funding (institution): AbbVie, BeiGene, Janssen/Pharmacyclics, Roche; travel/accommodations/expenses: AbbVie, Gilead, Janssen-Cilag, Roche.

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Anthony Mato, MD, MSCE: research support: AbbVie, Acerta/AstraZeneca, Adaptive, DTRM BioPharma, Johnson & Johnson, Loxo Oncology, Nurix, Genmab, Pharmacyclics, Regeneron, Sunesis, TG Therapeutics; consultant: AbbVie, Acerta/AstraZeneca, Adaptive, Celgene, DTRM BioPharma, Johnson & Johnson, Nurix, Genmab, LOXO, Genentech, AZ, Pharmacyclics, Sunesis, TG Therapeutics, Verastem.

Lydia Scarfò, MD

Assistant Professor
Internal Medicine
Università Vita-Salute San Raffaele
Consultant Hematologist
Strategic Research Program on CLL
Milan, Italy

Lydia Scarfò, MD: honoraria: AbbVie, AstraZeneca, BeiGene, Janssen, Octapharma; travel grants: BeiGene, Janssen.

Julie M. Vose, MD

Neumann M. and Mildred E. Harris Professor
Chief
, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Julie M. Vose, MD, MBA: consulting/advisory: AstraZeneca, Abbvie, Caribou, Daiichi Sankyo, Lilly, Genentech, MEI Pharma, Morphosys, Pharmacyclics